28 October, 2024 in Investor Relations Nexalin Technology Announces Landmark Study on Alzheimer’s Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer’s Disease
22 October, 2024 in Investor Relations Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
20 October, 2024 in Videos No More Side Effects: Nexalin’s Non-Invasive Approach to Treating Depression & PTSD
17 October, 2024 in Investor Relations New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients
14 October, 2024 in Investor Relations Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
